Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

Study Identifier
190342-033D
CT.gov Identifier
NCT01080209
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Eye Care
    • Study Drug
  • Brimo PS DDS®
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason * Applicable studies: Previous Allergan intravitreal Brimo PS DDS® treatment studies
    Exclusion Criteria:
    \- None

    Protocol Summary

    This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

    Study Locations

    Location
    Status
    Location
    Artesia, California, United States
    Status
    Not applicable
    Location
    Sydney, New South Wales, Australia
    Status
    Not applicable
    Location
    Westmead, New South Wales, Australia
    Status
    Not applicable
    Location
    Brno, Czech Republic
    Status
    Not applicable
    Location
    Paris, France
    Status
    Not applicable
    Location
    Karlsruhe, Germany
    Status
    Not applicable
    Showing {first} - {last} of {total} Results